[1]
|
Commission, R.B.N.H. and National Administration of Traditional Chinese Medicine (2022) Diagnosis and Treatment Protocol for COVID-19 Patients (Trial Version 9). Health Care Science, 1, 14-28. https://doi.org/10.1002/hcs2.1
|
[2]
|
Li, L. (2022) Development of China’s Health Care System in the Time of COVID-19: Challenges, Opportunities, and Call for Actions. Health Care Science, 1, 33-40. https://doi.org/10.1002/hcs2.4
|
[3]
|
Dagan, N., Barda, N., Kepten, E., et al. (2021) BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. The New England Journal of Medicine, 384, 1412-1423. https://doi.org/10.1056/NEJMoa2101765
|
[4]
|
Dai, M., Liu, D., Liu, M., et al. (2020) Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discovery, 10, 783-791.
https://doi.org/10.1158/2159-8290.CD-20-0422
|
[5]
|
Kuderer, N.M., Choueiri, T.K., Shah, D.P., et al. (2020) Clinical Impact of COVID-19 on Patients with Cancer (CCC19): A Cohort Study. The Lancet, 395, 1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9
|
[6]
|
Agbarya, A., Sarel, I., Ziv-Baran, T., et al. (2021) Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers, 13, Article 4191.
https://doi.org/10.3390/cancers13164191
|
[7]
|
Funakoshi, Y., Yakushijin, K., Ohji, G., et al. (2022) Safety and Immunogenicity of the COVID-19 Vaccine BNT162b2 in Patients Undergoing Chemotherapy for Solid Cancer. Journal of Infection and Chemotherapy, 28, 516-520.
https://doi.org/10.1016/j.jiac.2021.12.021
|
[8]
|
Massarweh, A., Eliakim-Raz, N., Stemmer, A., et al. (2021) Evalua-tion of Seropositivity following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncology, 7, 1133-1140. https://doi.org/10.1001/jamaoncol.2021.2155
|
[9]
|
Chen, Z., Zhu, P., Liu, Z., et al. (2022) Weakened Humoral Immune Responses of Inactivated SARS-CoV-2 Vaccines in Patients with Solid Tumors. Cancer Communications, 43, 280-284. https://doi.org/10.1002/cac2.12368
|
[10]
|
Cavanna, L., Proietto, M., Citterio, C., et al. (2022) COVID-19 Vaccination in Cancer Patients Older than 70 Years Undergoing Ac-tive Treatment. Seroconversion Rate and Safety. Vaccines, 10, Article 164.
https://doi.org/10.3390/vaccines10020164
|
[11]
|
Guven, D.C., Sahin, T.K., Kilickap, S. and Uckun, F.M. (2021) Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. Frontiers in Oncology, 11, Article 759108. https://doi.org/10.3389/fonc.2021.759108
|
[12]
|
Harrell Jr, F.E., Califf, R.M., Pryor, D.B., et al. (1982) Evaluating the Yield of Medical Tests. The Journal of the American Medical Association, 247, 2543-2546. https://doi.org/10.1001/jama.1982.03320430047030
|
[13]
|
Vickers, A.J., Cronin, A.M., Elkin, E.B. and Gonen, M. (2008) Extensions to Decision Curve Analysis, a Novel Method for Evaluating Diagnostic Tests, Prediction Models and Molecular Markers. BMC Medical Informatics and Decision Making, 8, Article No. 53. https://doi.org/10.1186/1472-6947-8-53
|
[14]
|
Herzog Tzarfati, K., Gutwein, O., Apel, A., et al. (2021) BNT162b2 COVID-19 Vaccine Is Significantly Less Effective in Patients with Hematologic Malignancies. American Journal of Hematology, 96, 1195-1203.
https://doi.org/10.1002/ajh.26284
|
[15]
|
Korayem, G.B., Aljuhani, O., Altebainawi, A.F., et al. (2022) The Safety and Effectiveness of Tocilizumab in Older Adult Critically Ill Patients with COVID-19: A Multicenter, Cohort Study. In-ternational Journal of Infectious Diseases, 122, 252-259. https://doi.org/10.1016/j.ijid.2022.05.038
|
[16]
|
Kumar Rai, G., Saluja, T., Chaudhary, S., et al. (2022) Safety and Immunogenicity of the Vi-DT Typhoid Conjugate Vaccine in Healthy Volunteers in Nepal: An Observer-Blind, Active-Controlled, Randomised, Non-Inferiority, Phase 3 Trial. The Lancet Infectious Diseases, 22, 529-540. https://doi.org/10.1016/S1473-3099(21)00455-2
|
[17]
|
Ariamanesh, M., Porouhan, P., Peyroshabany, B., et al. (2022) Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Investigation, 40, 26-34.
https://doi.org/10.1080/07357907.2021.1992420
|
[18]
|
Zhao, L. (2022) A Review of Healthy Aging in China, 2000-2019. Health Care Science, 1, 111-118.
https://doi.org/10.1002/hcs2.9
|
[19]
|
Amatu, A., Pani, A., Patelli, G., et al. (2022) Impaired Seroconversion after SARS-CoV-2 mRNA Vaccines in Patients with Solid Tumours Receiving Anticancer Treatment. European Journal of Cancer, 163, 16-25.
https://doi.org/10.1016/j.ejca.2021.12.006
|
[20]
|
Thomas, N., Gurvich, C. and Kulkarni, J. (2021) Sex Differences and COVID-19. In: Guest, P.C., Ed., Identification of Biomarkers, New Treatments, and Vaccines for COVID-19, Springer, Cham, 79-91.
https://doi.org/10.1007/978-3-030-71697-4_6
|
[21]
|
Fischinger, S., Boudreau, C.M., Butler, A.L., Streeck, H. and Alter, G. (2019) Sex Differences in Vaccine-Induced Humoral Immunity. Seminars in Immunopathology, 41, 239-249. https://doi.org/10.1007/s00281-018-0726-5
|
[22]
|
Ruggeri, E.M., Nelli, F., Fabbri, A., et al. (2022) Antineoplastic Treatment Class Modulates COVID-19 mRNA-BNT162b2 Vaccine Immunogenicity in Cancer Patients: A Secondary Analysis of the Prospective Vax-On Study. ESMO Open, 7, Article ID: 100350. https://doi.org/10.1016/j.esmoop.2021.100350
|
[23]
|
Erdoğan, A.P., Ekinci, F., Akçali, S. and Göksel, G. (2022) Factors Affecting the Serologic Response to SARS-CoV-2 Vaccination in Patients with Solid Tumors: A Prospective Study. Journal of Infection and Chemotherapy, 28, 1310-1316. https://doi.org/10.1016/j.jiac.2022.05.021
|
[24]
|
Ogega, C.O., Skinner, N.E., Blair, P.W., et al. (2021) Durable SARS-CoV-2 B Cell Immunity after Mild or Severe Disease. Journal of Clinical Investigation, 131, e145516. https://doi.org/10.1172/JCI145516
|
[25]
|
Eyu, P., Elyanu, P., Ario, A.R., et al. (2022) Investigation of Possible Preventable Causes of COVID-19 Deaths in the Kampala Metropolitan Area, Uganda, 2020-2021. International Journal of Infectious Diseases, 122, 10-14.
https://doi.org/10.1016/j.ijid.2022.05.033
|
[26]
|
Yasin, A.I., Aydin, S.G., Sümbül, B., et al. (2022) Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study. Future Medicine, 18, 1235-1244.
https://doi.org/10.2217/fon-2021-1248
|
[27]
|
Canetti, M., Barda, N., Gilboa, M., et al. (2022) Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. The New England Journal of Medicine, 387, 2092-2094. https://doi.org/10.1056/NEJMc2211283
|
[28]
|
Localio, A.R. and Goodman, S. (2012) Beyond the Usual Prediction Accuracy Metrics: Reporting Results for Clinical Decision Making. Annals of Internal Medicine, 157, 294-295.
https://doi.org/10.7326/0003-4819-157-4-201208210-00014
|
[29]
|
Van Calster, B. and Vickers, A.J. (2015) Cali-bration of Risk Prediction Models: Impact on Decision-Analytic Performance. Medical Decision Making, 35, 162-169. https://doi.org/10.1177/0272989X14547233
|